Physician profile
Edward A Stadtmauer
NPI 1457394744
$72,309.50
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 80% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $13K · 2021: $20K · 2022: $9,088 · 2023: $582 · 2024: $6,932 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $2,486 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,057.50 |
| Food and Beverage | $2,486.46 |
| Travel and Lodging | $427.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15,114.67 | 2021-2025 | |
| Janssen Biotech, INC. | $12,227.88 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $9,872.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $8,037.50 | 2020-2022 | |
| Amgen INC. | $6,738.16 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $5,895.00 | 2020 | |
| Celgene Corporation | $5,153.02 | 2019-2022 | |
| Genentech, INC. | $2,885.27 | 2019 | |
| Kite Pharma, INC. | $2,311.16 | 2019 | |
| National Marrow Donor Program | $2,169.63 | 2022-2025 | |
| Secura Bio, INC. | $1,500.00 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $123.41 | 2022 | |
| Astrazeneca Uk Limited | $120.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $111.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.27 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $12.86 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stadtmauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.